Dr. Tomasson Reports Early Data from MagentisMM-20
By Michael H. Tomasson, MD - Last Updated: February 18, 2025Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma. In a small study, all 12 patients responded, with manageable side effects. This combination may help advanced cases, according to the study investigators. Dr. Tomasson highlights ongoing research into bispecific antibodies, chimeric antigen receptor T-cell therapy, and the path toward a cure for patients with multiple myeloma.
Advertisement
Advertisement
Related Posts
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Dr. Parekh discussed the promising future of trispecifics, the group of patients with the largest unmet need, and more.
Investigators assert clinical trial design features may have contributed to this antibody-drug conjugate's loss of approvals.
Samir Parekh, MD, Appointed Director of the Center of Excellence for Multiple Myeloma at Mount Sinai
Dr. Parekh’s laboratory focuses on developing personalized treatment strategies for patients with multiple myeloma.
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.